April 28, 2016
Recommended Topic Related To:

Ca-DTPA

"Today, the U.S. Food and Drug Administration approved Xuriden (uridine triacetate), the first FDA-approved treatment for patients with hereditary orotic aciduria. Hereditary orotic aciduria is a rare metabolic disorder, which has been reported in"...

A A A

Ca-DTPA

Overdosage
Contraindications

OVERDOSE

In previous clinical studies, three deaths were reported in patients with severe hemochromatosis who were treated with daily IM Ca-DTPA (pentetate calcium trisodium inj) dosed up to 4 gram per day to reduce iron stores. One patient became comatose and died after receiving a total of 14 gram Ca-DTPA (pentetate calcium trisodium inj) , and the other two died after two weeks of daily treatment. Causal association with these events and the drug has not been established. (See WARNINGS)

CONTRAINDICATIONS

None known.

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 1/7/2009

Overdosage
Contraindications

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.